Physician profile
Bradley Doeden
NPI 1780644047
$666.39
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $223 · 2021: $154.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $121.36 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $100.75 | 2019-2021 | |
| Amgen INC. | $68.86 | 2019-2020 | |
| Medtronic Minimed, INC. | $62.79 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $50.60 | 2019-2020 | |
| Dexcom, INC. | $36.71 | 2020 | |
| Companion Medical, INC. | $34.73 | 2019-2020 | |
| Radius Health, INC. | $26.80 | 2020-2021 | |
| Lifescan, INC. | $26.18 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.08 | 2019-2021 | |
| Novo Nordisk INC | $22.11 | 2019-2020 | |
| Abbott Laboratories | $21.10 | 2019 | |
| Medtronic, INC. | $17.23 | 2021 | |
| Valeritas, INC. | $13.98 | 2019 | |
| Horizon Therapeutics Plc | $12.89 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $12.61 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.61 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Doeden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.